11 completed. 9 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
| Phase 2 | 2 | Completed 2 |
Follow ervogastat: new trials by email Literature Review of ervogastat trials Research Report on ervogastat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571. Oral [14C]PF-06865571, Oral PF-06865571, IV [14C]PF-06865571 - Healthy Participants | Phase 1 | Completed | Pfizer | 6 | 2021-05-11 | 2024-07-31 |
| A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571 - Healthy Volunteer | Phase 1 | Completed | Pfizer | 27 | 2021-04-05 | 2023-08-21 |
| Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis PF-06865571, PF-05221304, Placebo - Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease | Phase 2 | Completed | Pfizer | 75 | 2020-08-10 | 2023-04-13 |
| Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) Placebo, PF-06865571, PF-05221304 - Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis | Phase 2 | Completed | Pfizer | 256 | 2020-06-15 | 2025-03-21 |
| Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects PF-06865571 100 mg - Hepatic Impairment, Healthy Volunteers | Phase 1 | Completed | Pfizer | 24 | 2019-10-03 | 2021-04-13 |
| Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants PF-06865571 400 mg Immediate Release (IR) in Fed State, PF-06865571 50 mg Modified Release (MR) in Fed State, PF-06865571 400 mg MR in Fed State - Healthy Participants | Phase 1 | Completed | Pfizer | 12 | 2019-08-13 | 2019-11-27 |
| Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics Metformin, PF-06865571 - Healthy Volunteers | Phase 1 | Completed | Pfizer | 18 | 2018-08-17 | 2019-03-28 |
| 2-Week Study In People With Nonalcoholic Fatty Liver Disease Placebo, PF-06865571 - Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease | Phase 1 | Completed | Pfizer | 48 | 2018-06-21 | 2020-03-13 |
| A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects PF-06865571 Immediate release suspension, PF-06865571 Slow release MR tablets, PF-06865571 Fast release MR tablets - Healthy | Phase 1 | Completed | Pfizer | 12 | 2018-01-19 | 2018-04-17 |
| A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects PF-06865571, Placebo - Healthy Subjects | Phase 1 | Completed | Pfizer | 60 | 2017-08-01 | 2018-05-23 |
| Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571 PF-06865571, Placebo - Healthy | Phase 1 | Completed | Pfizer | 17 | 2017-03-16 | 2017-08-14 |
Non-alcoholic Fatty Liver Disease (4)
Pfizer (11)
United States (8) · Belgium (4) · Canada (2) · Bulgaria (1) · China (1) · Hong Kong (1) · India (1) · Japan (1) · Poland (1) · Puerto Rico (1) · Slovakia (1) · South Korea (1) · Taiwan (1)
PMID 36690550, PMID 35354614, PMID 40753985
2017 (2), 2019 (2), 2018 (1)